Eli Lilly: Jardiance Reduces Risk Of Kidney Disease Progression In Diabetes

(RTTNews) - Boehringer Ingelheim and Eli Lilly and Company (LLY) announced findings from two new analyses of the EMPA-REG OUTCOME trial. The results included a post-hoc analysis demonstrating consistent effects for Jardiance versus placebo on renal outcomes in patients with established cardiovascular disease and type 2 diabetes, irrespective of control of certain CV risk factors.

The new post-hoc analysis of the EMPA-REG OUTCOME trial showed Jardiance consistently reduced the risk of new or worsening kidney disease versus placebo irrespective of control of blood pressure, low-density lipoprotein cholesterol or A1C levels, individually or combined.

Separately, the effect of Jardiance versus placebo on CV outcomes was examined in a post-hoc analysis of sub-groups of EMPA-REG OUTCOME defined by CV risk at trial start - low, intermediate, high and highest risk. The company said the findings demonstrated consistent reductions in the risk of CV death with Jardiance compared with placebo independent of CV risk group.